2Kim MR, Kim A, Jo MY, et al. High frequency of endometrial polyps in endometriosis. J Am Assoc Gynecol Laparosc, 2003, 10(1):46-48.
3Taylor LJ, Jackson TL, Reid JG, et al. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki-67 in endometrial oolvDs. B JOG, 2003, 110(9):794-798.
4Tallini G, Vanni R, Manfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas,pulmonary chondroid hamartomas, endometrial polyps and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest, 2000, 80(1): 359-369.
5Hague S, Manek S, Oehler MK, et al. Tamoxifen induction of angiogenic factor expression in endometrium. Br J Cancer, 2002, 86(5):761-767.
6Chavez NF, Garner EO, Khan W, et al. Does the introduction of new technology change population demographics? Minimally invasive technologies and endometrial polyps. Gynecol Obstet Invest, 2002,54(4): 217-220.
7Savelli L, laco PD, Santini D, et al. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. J Am Assoc Gynecol Laparosc, 2003,188(4): 927-931.
8Bouda JJ, Hradecky L, Rokyta Z. Hysteroscopic polypectomy versus fractionated curettage in the treatment of corporal polyps-recurrence of corporal polyps. Ceska Gynekol, 2000, 65(3): 147-151.
9Hachisuga T,Miyakawa T, Tsujioka H, et al. K-ras mutation in tamoxifen-related endometrial polyps. Cancer, 2003, 98(9): 1890-1897.
10Clark TJ, Khan KS, Gupta JK. Current practice for the treatment of benign intrauterine polyps: a national questionnaire survey of consultant gynaecologists in UK. Eur J Obstet Gynecol Reprod Biol, 2002,103(1): 65-67.
